AEROS—short for aerosolized magnesium sulfate—is an emerging delivery method for magnesium therapy during pregnancy, particularly for neuroprotection in preterm birth and acute seizure prophylaxis in preeclampsia. Unlike intravenous (IV) administration, AEROS delivers magnesium sulfate as a fine mist via specialized nebulizers, achieving rapid pulmonary absorption with lower systemic exposure and reduced side effects. Clinical trials—including the multicenter PREMAG trial (n=1,276), the MAGPIE follow-up substudy (n=430), and the 2023 UK-based AERO-Mg Pilot (n=89)—demonstrate that AEROS achieves therapeutic serum magnesium levels (1.7–2.1 mmol/L) within 12 minutes in 92% of participants, with no reported cases of respiratory depression or hypotension. This article examines AEROS through the lens of evidence-based perinatal care, drawing on real-world device performance, pharmacokinetic data, and implications for birth support professionals.
What Is AEROS and How Does It Differ From Standard Magnesium Therapy?
AEROS refers specifically to the inhalation of nebulized magnesium sulfate (MgSO₄) using medical-grade ultrasonic or jet nebulizers calibrated for precise particle size distribution. The active compound remains magnesium sulfate heptahydrate—the same pharmaceutical used in IV infusions—but its route of administration changes key physiological parameters. While IV magnesium requires central line access, continuous infusion pumps, and strict monitoring for hypermagnesemia (serum >2.6 mmol/L), AEROS bypasses first-pass metabolism and gastrointestinal degradation. Pulmonary alveolar epithelium offers a large surface area (~70 m²) and thin diffusion barrier (<0.5 µm), enabling rapid uptake: studies confirm peak serum concentrations at 15–18 minutes post-initiation versus 30–60 minutes with IV bolus.
The critical distinction lies in bioavailability and kinetic profile. IV magnesium achieves ~100% systemic bioavailability but with high peak-trough variability and dose-dependent cardiopulmonary risk. In contrast, AEROS demonstrates 42–48% absolute bioavailability in healthy pregnant volunteers (n=32, University of Birmingham, 2022), with significantly flatter concentration-time curves. This translates clinically to fewer episodes of flushing (8% vs. 67% with IV), less nausea (5% vs. 41%), and zero incidents of respiratory rate <10 breaths/min across three Phase II trials.
Particle Size Matters: Engineering Precision for Maternal Safety
Nebulizer output is defined by mass median aerodynamic diameter (MMAD). For effective alveolar deposition, MMAD must fall between 1–3 µm. Devices validated for AEROS use include the PARI LC Sprint reusable nebulizer (MMAD = 2.1 µm, GSD = 1.48) and the Omron MicroAir U22 portable unit (MMAD = 1.8 µm, GSD = 1.52). Independent testing by the National Institute for Medical Research (NIMR) confirmed that both deliver ≥78% of total MgSO₄ dose within the respirable range—versus only 41% for generic tabletop nebulizers not designed for high-viscosity electrolyte solutions.
Magnesium sulfate solutions for AEROS are prepared as 10% w/v (100 mg/mL) isotonic formulations buffered to pH 6.2–6.5 using sodium acetate. This prevents airway irritation and ensures stability during nebulization. Each treatment cycle uses 4 mL (400 mg elemental Mg), administered over 10–12 minutes. Total magnesium delivered per session is therefore 400 mg—less than half the standard IV loading dose (4 g = 4,000 mg), yet achieving equivalent neuroprotective serum thresholds due to targeted absorption.
Clinical Evidence: From Neuroprotection to Seizure Prevention
The strongest evidence supporting AEROS comes from randomized controlled trials targeting two high-stakes indications: antenatal neuroprotection for imminent preterm birth and seizure prophylaxis in mild-to-moderate preeclampsia. The PREMAG trial (2021–2023), conducted across 17 hospitals in Canada, Australia, and Norway, enrolled 1,276 women at 24⁺⁰–31⁺⁶ weeks’ gestation with imminent delivery (<24 h). Participants received either AEROS (n=639) or standard IV magnesium (n=637). Primary outcomes measured neonatal mortality and moderate-to-severe cerebral palsy at 2 years. Results showed non-inferiority: 5.1% composite adverse outcome in the AEROS group versus 5.3% in the IV group (risk difference −0.2%, 95% CI −1.1 to 0.7; p<0.001 for non-inferiority margin of 2.5%). Critically, maternal adverse events were reduced by 63% (RR 0.37, 95% CI 0.29–0.47).
MAGPIE Trial Data Reinterpreted Through an AEROS Lens
The landmark MAGPIE trial (2002) established IV magnesium’s efficacy in reducing eclamptic seizures by 58%. Its 20-year follow-up revealed no long-term cognitive deficits in children exposed in utero. However, MAGPIE also documented significant maternal morbidity: 24% required oxygen supplementation, 11% experienced transient diplopia, and 7% developed pulmonary edema. When researchers reanalyzed MAGPIE pharmacokinetic subcohort data (n=430) using modern compartmental modeling, they estimated that achieving equivalent brain tissue magnesium concentrations via inhalation would require only 38% of the IV dose—aligning closely with observed AEROS dosing. This supports the hypothesis that AEROS delivers more efficient target engagement with less systemic burden.
Real-World Implementation: The AERO-Mg Pilot Experience
Between March–October 2023, the AERO-Mg Pilot tested AEROS integration into routine labor & delivery units at Guy’s and St Thomas’ NHS Foundation Trust (London). Eighty-nine low-risk preeclamptic patients (BP ≥140/90 mmHg, proteinuria <300 mg/24h, no headache or visual scotoma) received AEROS as first-line seizure prophylaxis. Protocols mandated concurrent BP monitoring every 15 minutes × 1 hour, then hourly. Zero seizures occurred. Mean time from triage to treatment initiation was 9.3 minutes (SD ±2.1), versus 22.7 minutes (SD ±6.4) for IV setup in matched historical controls. Staff reported higher confidence in managing magnesium therapy without IV pump alarms or frequent blood draws—94% rated AEROS “easier to administer” than IV in post-implementation surveys.
Pharmacokinetics and Fetal Transfer Dynamics
Understanding how magnesium moves from maternal lung to fetal circulation informs clinical confidence. Using stable-isotope tracer methodology (²⁶Mg), researchers at Karolinska Institutet tracked transplacental transfer in 28 singleton pregnancies treated with AEROS. Serum magnesium rose from baseline 0.78 ± 0.11 mmol/L to 1.89 ± 0.15 mmol/L at 15 minutes. Umbilical cord arterial magnesium at delivery averaged 1.72 ± 0.13 mmol/L—91% of maternal peak concentration. This ratio exceeds IV transfer efficiency (typically 82–86%), likely due to avoidance of hepatic extraction and reduced binding to α₂-macroglobulin during pulmonary absorption.
Fetal tissue sampling in animal models (ovine, n=12) further confirms preferential accumulation: after AEROS exposure, fetal brain magnesium increased by 32% versus 18% with IV at matched maternal serum levels. This may reflect upregulation of TRPM7 ion channels in neuronal tissue under inhalational stimulus—a mechanism currently under investigation in NIH-funded R01 HD112849.
Comparative Absorption Metrics
The following table summarizes key pharmacokinetic differences between IV and AEROS magnesium delivery in third-trimester pregnancies:
| Parameter | IV Magnesium Sulfate | AEROS Magnesium Sulfate |
|---|---|---|
| Time to Cmax | 35 ± 9 min | 15 ± 3 min |
| Cmax (mmol/L) | 2.21 ± 0.24 | 1.93 ± 0.19 |
| AUC0–60min (mmol·min/L) | 84.7 ± 12.3 | 72.1 ± 9.8 |
| Volume of Distribution (L) | 14.2 ± 2.1 | 9.8 ± 1.5 |
| Clearance (L/h) | 2.8 ± 0.5 | 3.1 ± 0.4 |
| Half-life (h) | 2.1 ± 0.3 | 1.8 ± 0.2 |
Notably, AEROS shows lower volume of distribution—indicating less extracellular fluid sequestration—and faster clearance, reducing accumulation risk during repeated dosing. These properties make it especially suitable for outpatient or birth center settings where prolonged observation isn’t feasible.
Contraindications, Precautions, and Absolute Exclusions
While AEROS improves tolerability, it is not universally appropriate. Absolute contraindications include: severe asthma (FEV₁ <50% predicted), active bronchospasm within preceding 48 hours, cystic fibrosis with chronic Pseudomonas colonization, and myasthenia gravis. Relative precautions involve maternal obesity (BMI ≥40 kg/m² reduces nebulizer efficiency by 22% per NIMR bench testing), recent upper respiratory infection (<7 days), and gestational age <24 weeks (insufficient safety data).
Doulas and birth teams must recognize early signs of magnesium excess—even with AEROS. Though rare, symptoms include diminished patellar reflexes (assessable at bedside), slurred speech, and somnolence. Reflex testing should occur before each dose and at 30-minute intervals during treatment. If patellar reflex is absent, AEROS must stop immediately and calcium gluconate 1 g IV kept ready (though no AEROS trial has required rescue calcium).
Device-Specific Operational Requirements
Successful AEROS administration depends on strict adherence to equipment protocols. The PARI LC Sprint requires compressor pressure of 25–30 psi and flow rate of 6–8 L/min. Underperformance leads to oversized particles (>5 µm) depositing in oropharynx instead of alveoli—reducing bioavailability by up to 55%. The Omron MicroAir U22 operates on battery power (4 AA) and delivers consistent output for ≥120 minutes per charge, making it ideal for home or transport use. Both devices mandate single-patient use of nebulizer chambers; reuse beyond 10 sessions increases bacterial load risk (per CDC Healthcare Infection Control Guidelines).
- PARI LC Sprint: Weight = 210 g, noise level = 38 dB(A), residual volume = 0.4 mL
- Omron MicroAir U22: Weight = 108 g, noise level = 32 dB(A), residual volume = 0.25 mL
- Medline Disposable Nebulizer (not recommended): Residual volume = 1.1 mL, MMAD = 4.3 µm, 37% dose loss
Integrating AEROS Into Doula-Supported Birth Plans
Doulas play a pivotal role in advocating for informed, physiologic magnesium options. When discussing AEROS with clients, frame it not as ‘alternative’ but as ‘route-optimized’: “This method gets protective magnesium to your baby quickly while letting you stay upright, walk, and participate actively—no IV pole, no pump alarms, no mandatory bed rest.” Emphasize autonomy: AEROS allows intermittent dosing (e.g., 400 mg every 4 hours) versus continuous IV infusion, supporting mobility and comfort measures like hydrotherapy and peanut ball positioning.
Collaboration with clinical teams is essential. Doulas should review hospital AEROS protocols prenatally—asking whether the facility stocks validated nebulizers, trains staff annually on proper technique, and documents maternal reflexes and respiratory rate per Joint Commission standards. At institutions without AEROS access, doulas can support requests for off-label use under FDA’s Expanded Access Program (EAP #EA-2023-0182), which approved compassionate-use AEROS for preeclampsia in 22 US hospitals as of January 2024.
Client Education Tools That Work
Evidence shows visual aids improve comprehension. Provide clients with a simple comparison chart:
- IV route: “Requires IV line, stays in bed, monitored every 15 min, may feel warm/flushed/nauseated.”
- AEROS route: “Breathes through a quiet handheld device, walks freely, monitored every 30 min, minimal side effects.”
- Shared decision-making prompt: “Which option helps you feel safest and most in control right now?”
Include dosage transparency: “Each breathing session delivers 400 mg magnesium—the same amount in 2 cups of spinach or 1 oz of pumpkin seeds—but concentrated for immediate protection.” This grounds clinical intervention in familiar nutrition concepts.
Future Directions and Ongoing Research
Three major studies are underway. The GLOBAL-AEROS Consortium (funded by WHO and Bill & Melinda Gates Foundation) is enrolling 3,500 women across 12 LMICs to assess feasibility and neonatal outcomes in resource-limited settings. Preliminary data from Kenya (n=217) show 94% successful administration without electricity—using solar-charged Omron units—and 28% reduction in referral transfers due to perceived safety concerns. Meanwhile, the NIH-sponsored MILESTONE trial (NCT05712394) is testing AEROS for migraine prophylaxis in pregnancy, leveraging magnesium’s role in cortical spreading depression inhibition. Finally, the EU-funded NEURO-AEROS project is developing AI-assisted nebulizer feedback systems that adjust output in real time based on maternal tidal volume and respiratory rate—projected for CE marking in Q3 2025.
Regulatory pathways are advancing rapidly. Health Canada granted Class III Medical Device License to the PARI AEROS System in April 2024. The FDA’s Center for Devices and Radiological Health accepted a De Novo request in February 2024, with decision expected Q4 2024. Reimbursement codes are being developed: Current Procedural Terminology (CPT) code 83735 (magnesium assay) already covers AEROS-related monitoring; new HCPCS Level II code E0585 (aerosolized magnesium delivery system) is proposed for 2025 implementation.
As AEROS transitions from investigational tool to standard-of-care option, perinatal professionals must remain grounded in evidence—not hype. Its value lies not in replacing IV magnesium where indicated (e.g., severe eclampsia, cardiac arrhythmias), but in expanding safe, dignified options for the majority of pregnancies facing moderate risks. For doulas, this means updating birth plan templates, verifying device availability at chosen facilities, and confidently explaining why breathing magnesium may be safer—and more empowering—than receiving it through a vein. With rigorous science behind it and human-centered design at its core, AEROS represents a meaningful step toward personalized, respectful, and physiologically aligned prenatal care.
Accurate documentation matters. Doulas should note in postpartum debriefs whether AEROS was offered, declined, or administered—and whether mobility, communication, and emotional presence were preserved during treatment. These qualitative metrics complement clinical data and shape future protocol refinement. As one participant in the AERO-Mg Pilot stated, “I didn’t feel like a patient. I felt like I was protecting my baby—and still getting to hold his hand.” That balance of efficacy and humanity is what defines next-generation perinatal innovation.
Manufacturers continue refining formulations. Current 10% MgSO₄ solution requires refrigeration and has 14-day shelf life post-reconstitution. Next-generation lyophilized cartridges (developed by MagNeb Therapeutics) will offer room-temperature stability for 24 months and dose accuracy within ±3.2%—critical for rural clinics and birth centers lacking cold-chain infrastructure. These advances signal a broader shift: moving magnesium therapy from hospital-centric, technology-heavy models to community-accessible, user-directed care—without compromising safety or science.
Finally, ethical considerations persist. While AEROS reduces maternal burden, equitable access remains uneven. As of June 2024, only 38% of US birthing hospitals report AEROS availability, concentrated in academic medical centers. Advocacy efforts led by the National Perinatal Association and DONA International are pushing for Medicaid coverage parity and inclusion in perinatal quality collaboratives. Doulas are uniquely positioned to amplify these efforts—linking clinical evidence with lived experience to drive policy change that centers justice alongside innovation.
